SCHWIND AMARIS: already providing excellent results

Article

Schwind eye-tech-solution's latest unveiling, the SCHWIND AMARIS excimer laser, provides excellent visual acuity (VA) results, high predictability and low variance in results.

Schwind eye-tech-solution's latest unveiling, the SCHWIND AMARIS excimer laser, provides excellent visual acuity (VA) results, high predictability and low variance in results, according to Maria-Clara Arbelaez, MD from Oman, speaking at the Schwind lunchtime symposium.

Dr Arbelaez's claims follow the results of a multicentre study, which was conducted by the Oman doctor along with Ioannis Aslanides, MD (Greece), Francesco Carones, MD (Italy), Tobias Neuhann, MD (Germany), as well as Alena Feuermannova, MD and Pavel Rozsival, MD (Czech Republic). The purpose of the study was to evaluate the outcomes of AMARIS-LASIK aberration free treatments for myopia and myopic astigmatism.

A total of 454 myopic eyes, either pure or with astigmatism, underwent "Aberration Free" treatment with the SCHWIND AMARIS. Preoperative spherical equivalent (SE) ranged from -0.50 D to -8.5 D (mean -3.54 D±1.67 D) and sphere and cylinder was treated up to -9 D and -7 D, respectively.

The mean postoperative SE at one-month follow-up was -0.16 with a low standard deviation of 0.26 D. In 74% of eyes, the planned refractive result was achieved within ±0.25 D after one month, 93% were within ±0.50 D and 100% were within ±1.00 D. High postoperative stability was observed after just one week.

By one-month follow-up, 92% of eyes had attained an uncorrected visual acuity (UCVA) of 20/20 or better, 99% of eyes achieved a UCVA of 20/25 or better and 43% of eyes achieved a VA of 20/16 or better. No eyes had a VA of less than 20/32.

"These results were obtained without applying additional nomograms," confirmed Dr Arbelaez. "In my opinion, the extraordinary performance of the SCHWIND AMARIS decisively contributed to the excellent clinical results that we have seen so far. Although further follow-up is required to evaluate overall stability, I truly believe that aberration free treatments with the Schwind AMARIS are safe and predictable," she concluded.

Recent Videos
David Yorston, FRCS, FRCOphth, discusses his EURETINA keynote lecture
Hoda Shamsnajafabadi, MSc, PhD, presents at the 2024 EURETINA meeting
Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab
Carl Awh, MD, FASRS, speaks about the American Society of Retina Specialists (ASRS) at EURETINA
Stefano Mercuri, MD, first author of the winning eposter “Genotype-phenotype correlations in a cohort of genetically determined Retinitis Pigmentosa (RP) Italian patients with Rho gene mutations”
Bahram Bodaghi, MD, PHD, FEBO at the 2024 EURETINA meeting
Enrico Borrelli, MD, FEBO, speaks at EURETINA
Aleksandra Rachitskaya, MD, FASRS, speaks about the Vit-Buckle Society at the 2024 EURETINA Congress.
© 2024 MJH Life Sciences

All rights reserved.